{
 "generated": "2026-11-01",
 "node": {
  "id": "org:iambic-therapeutics",
  "type": "Organization",
  "name": "Iambic Therapeutics",
  "org_type": "Developer",
  "kind": "company",
  "homepage": "https://www.iambic.ai/",
  "entry": "agent",
  "by": "episode-review",
  "at": "2026-10-29T08:20:02Z",
  "degree": 0.0011,
  "n_apps": 0,
  "n_models": 0
 },
 "page": "https://xiaopingfeng.com/graph/e/org/iambic-therapeutics/",
 "out": [],
 "in": [
  {
   "type": "invested_in",
   "sentence": "NVIDIA投资Iambic Therapeutics",
   "direction": "in",
   "id": "org:nvidia",
   "name": "NVIDIA",
   "note": "招股书披露英伟达是 Iambic 5% 以上股东之一；Reuters 称“英伟达参股”。Iambic 的 IPO 尚在递交条款阶段。",
   "status": "agent",
   "evidence": [
    {
     "kind": "filing",
     "label": "监管 / 法律文件",
     "text": "Iambic 的招股书披露英伟达为 5% 以上股东之一，主打药 IAM1363 已有超过 100 名受试者用药。",
     "url": "https://www.sec.gov/Archives/edgar/data/0001997038/000119312526396704/iam-20260921.htm"
    },
    {
     "kind": "own",
     "label": "本站页面",
     "text": "本站 AI Buzzwords EP.107 收录此事（单独条目快讯 · AI 做药与科学：Iambic Therapeutics 递出 IPO 条款）",
     "url": "https://xiaopingfeng.com/buzzwords/107/"
    }
   ]
  }
 ]
}